CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Files An 8-K Other EventsItem 9.01 Other Events.
On August 7, 2017, Cyclacel Pharmaceuticals, Inc. issued a press release announcing the selection of a recommended Phase 2 dose from part 1 of a dose-escalating, Phase 1, first-in-human clinical study of CYC065, a Cyclin Dependent Kinase 2/9 inhibitor. A copy of the press release is attached as Exhibit99.1 to this Current Report on Form 8-K, and the information contained therein is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
| Exhibit Number | Description |
| 99.1 | Press release, dated August 7, 2017 |
Cyclacel Pharmaceuticals, Inc. ExhibitEX-99.1 2 t1702303_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cyclacel Pharmaceuticals,…To view the full exhibit click here
About CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC)
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.